Efficib

Maa: Euroopan unioni

Kieli: englanti

Lähde: EMA (European Medicines Agency)

Osta se nyt

Pakkausseloste Pakkausseloste (PIL)
07-09-2023
Valmisteyhteenveto Valmisteyhteenveto (SPC)
07-09-2023

Aktiivinen ainesosa:

sitagliptin, metformin hydrochloride

Saatavilla:

Merck Sharp and Dohme B.V

ATC-koodi:

A10BD07

INN (Kansainvälinen yleisnimi):

sitagliptin, metformin

Terapeuttinen ryhmä:

Drugs used in diabetes

Terapeuttinen alue:

Diabetes Mellitus, Type 2

Käyttöaiheet:

For patients with type-2 diabetes mellitus:Efficib is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.Efficib is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.Efficib is indicated as triple combination therapy with a PPAR agonist (i.e. a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPAR agonist.Efficib is also indicated as add on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dosage of insulin and metformin alone do not provide adequate glycaemic control.

Tuoteyhteenveto:

Revision: 33

Valtuutuksen tilan:

Authorised

Valtuutus päivämäärä:

2008-07-15

Pakkausseloste

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDI
CINAL PRODUCT
Efficib 50 mg/850 mg film-
coated tablets
Efficib 50 mg/1,000 mg film-
coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Efficib 50 mg/850 mg film-coated tablets
Each tablet contains sitagliptin phosphate monohydrate
equivalent to 50
mg of sitagliptin and 850
mg
of metf
ormin hydrochloride.
Efficib 50 mg/1,000 mg film-coated tablets
Each tablet contains sitagliptin phosphate monohydrate
equivalent to 50
mg of sitagliptin and
1,000 mg of metf
ormin hydrochloride.
For the full list of
excipients, see section
6.1.
3.
PHARMACEUTICAL
FORM
Film-
coated tablet (tablet).
Efficib 50 mg/850 mg film-coated tablets
Capsule-sh
aped, pink film
-coated tablet with
“515” debossed on one side.
Efficib 50 mg/1,000 mg film-coated tablets
Capsule-shaped, red film-
coated tablet with “
577
” debossed on one side
.
4.
CLINICA
L PARTICULARS
4.1
THERAPEUTIC INDICATIONS
For adult
patients with type
2 diabetes mellitus:
Efficib
is indicated as an adjunct to diet and exercise to improve glycaemic
contro
l in patients
inadequately controlled on their maximal tolerated dose of met
fo
rmin alone or those already being
treated with the combination of
sitagliptin and
metformin.
Efficib
is indicated in combination with a sulphonylurea (i.e., triple
combination t
herapy) as an
adjunct to diet and exercise in patients inadequately controll
ed
on their maximal tolerated dose of
metformin and a s
u
lphonylurea.
Efficib
is indicated as tr
iple
combination therapy with a
peroxisome proliferator
-
activated receptor
gamma (PPAR

) agonist
(i.e., a thiazolidinedione) as an adjunct to diet and exercise
in patients
inadequately controlled on their maximal to
l
erated dose of metformin and a PPAR

agonist.
Efficib is also indicated as add
-
on to insulin (i.e., triple combination ther
apy) a
s an adjunct to diet and
exercise to improve glycaemic control in pati
en
ts when stable
dose
of insulin and metformin alone do
not provide adequate glycaemic contro
                                
                                Lue koko asiakirja
                                
                            

Valmisteyhteenveto

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDI
CINAL PRODUCT
Efficib 50 mg/850 mg film-
coated tablets
Efficib 50 mg/1,000 mg film-
coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Efficib 50 mg/850 mg film-coated tablets
Each tablet contains sitagliptin phosphate monohydrate
equivalent to 50
mg of sitagliptin and 850
mg
of metf
ormin hydrochloride.
Efficib 50 mg/1,000 mg film-coated tablets
Each tablet contains sitagliptin phosphate monohydrate
equivalent to 50
mg of sitagliptin and
1,000 mg of metf
ormin hydrochloride.
For the full list of
excipients, see section
6.1.
3.
PHARMACEUTICAL
FORM
Film-
coated tablet (tablet).
Efficib 50 mg/850 mg film-coated tablets
Capsule-sh
aped, pink film
-coated tablet with
“515” debossed on one side.
Efficib 50 mg/1,000 mg film-coated tablets
Capsule-shaped, red film-
coated tablet with “
577
” debossed on one side
.
4.
CLINICA
L PARTICULARS
4.1
THERAPEUTIC INDICATIONS
For adult
patients with type
2 diabetes mellitus:
Efficib
is indicated as an adjunct to diet and exercise to improve glycaemic
contro
l in patients
inadequately controlled on their maximal tolerated dose of met
fo
rmin alone or those already being
treated with the combination of
sitagliptin and
metformin.
Efficib
is indicated in combination with a sulphonylurea (i.e., triple
combination t
herapy) as an
adjunct to diet and exercise in patients inadequately controll
ed
on their maximal tolerated dose of
metformin and a s
u
lphonylurea.
Efficib
is indicated as tr
iple
combination therapy with a
peroxisome proliferator
-
activated receptor
gamma (PPAR

) agonist
(i.e., a thiazolidinedione) as an adjunct to diet and exercise
in patients
inadequately controlled on their maximal to
l
erated dose of metformin and a PPAR

agonist.
Efficib is also indicated as add
-
on to insulin (i.e., triple combination ther
apy) a
s an adjunct to diet and
exercise to improve glycaemic control in pati
en
ts when stable
dose
of insulin and metformin alone do
not provide adequate glycaemic contro
                                
                                Lue koko asiakirja
                                
                            

Asiakirjat muilla kielillä

Pakkausseloste Pakkausseloste bulgaria 07-09-2023
Valmisteyhteenveto Valmisteyhteenveto bulgaria 07-09-2023
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta bulgaria 05-07-2013
Pakkausseloste Pakkausseloste espanja 07-09-2023
Valmisteyhteenveto Valmisteyhteenveto espanja 07-09-2023
Pakkausseloste Pakkausseloste tšekki 07-09-2023
Valmisteyhteenveto Valmisteyhteenveto tšekki 07-09-2023
Pakkausseloste Pakkausseloste tanska 07-09-2023
Valmisteyhteenveto Valmisteyhteenveto tanska 07-09-2023
Pakkausseloste Pakkausseloste saksa 07-09-2023
Valmisteyhteenveto Valmisteyhteenveto saksa 07-09-2023
Pakkausseloste Pakkausseloste viro 07-09-2023
Valmisteyhteenveto Valmisteyhteenveto viro 07-09-2023
Pakkausseloste Pakkausseloste kreikka 07-09-2023
Valmisteyhteenveto Valmisteyhteenveto kreikka 07-09-2023
Pakkausseloste Pakkausseloste ranska 07-09-2023
Valmisteyhteenveto Valmisteyhteenveto ranska 07-09-2023
Pakkausseloste Pakkausseloste italia 07-09-2023
Valmisteyhteenveto Valmisteyhteenveto italia 07-09-2023
Pakkausseloste Pakkausseloste latvia 07-09-2023
Valmisteyhteenveto Valmisteyhteenveto latvia 07-09-2023
Pakkausseloste Pakkausseloste liettua 07-09-2023
Valmisteyhteenveto Valmisteyhteenveto liettua 07-09-2023
Pakkausseloste Pakkausseloste unkari 07-09-2023
Valmisteyhteenveto Valmisteyhteenveto unkari 07-09-2023
Pakkausseloste Pakkausseloste malta 07-09-2023
Valmisteyhteenveto Valmisteyhteenveto malta 07-09-2023
Pakkausseloste Pakkausseloste hollanti 07-09-2023
Valmisteyhteenveto Valmisteyhteenveto hollanti 07-09-2023
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta hollanti 05-07-2013
Pakkausseloste Pakkausseloste puola 07-09-2023
Valmisteyhteenveto Valmisteyhteenveto puola 07-09-2023
Pakkausseloste Pakkausseloste portugali 07-09-2023
Valmisteyhteenveto Valmisteyhteenveto portugali 07-09-2023
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta portugali 05-07-2013
Pakkausseloste Pakkausseloste romania 07-09-2023
Valmisteyhteenveto Valmisteyhteenveto romania 07-09-2023
Pakkausseloste Pakkausseloste slovakki 07-09-2023
Valmisteyhteenveto Valmisteyhteenveto slovakki 07-09-2023
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta slovakki 05-07-2013
Pakkausseloste Pakkausseloste sloveeni 07-09-2023
Valmisteyhteenveto Valmisteyhteenveto sloveeni 07-09-2023
Julkisesta arviointikertomuksesta Julkisesta arviointikertomuksesta sloveeni 05-07-2013
Pakkausseloste Pakkausseloste suomi 07-09-2023
Valmisteyhteenveto Valmisteyhteenveto suomi 07-09-2023
Pakkausseloste Pakkausseloste ruotsi 07-09-2023
Valmisteyhteenveto Valmisteyhteenveto ruotsi 07-09-2023
Pakkausseloste Pakkausseloste norja 07-09-2023
Valmisteyhteenveto Valmisteyhteenveto norja 07-09-2023
Pakkausseloste Pakkausseloste islanti 07-09-2023
Valmisteyhteenveto Valmisteyhteenveto islanti 07-09-2023
Pakkausseloste Pakkausseloste kroatia 07-09-2023
Valmisteyhteenveto Valmisteyhteenveto kroatia 07-09-2023

Etsi tähän tuotteeseen liittyviä ilmoituksia

Näytä asiakirjojen historia